CASI Pharmaceuticals, Inc. (CASI)

US — Healthcare Sector
Peers: ANNX  CDTX  CFRXQ  CLRB  CYCN  EPIX  GYRE  TPST 

Automate Your Wheel Strategy on CASI

With Tiblio's Option Bot, you can configure your own wheel strategy including CASI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CASI
  • Rev/Share 2.0247
  • Book/Share -0.5209
  • PB -2.5341
  • Debt/Equity -2.2914
  • CurrentRatio 0.8057
  • ROIC -1.6318

 

  • MktCap 20450364.0
  • FreeCF/Share 0.0
  • PFCF 0.0
  • PE -0.5052
  • Debt/Assets 0.453
  • DivYield 0
  • ROE -9.7255

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

CASI Pharmaceuticals Provides Business and Clinical Update
CASI
Published: May 19, 2025 by: Accesswire
Sentiment: Neutral

BEIJING, CHINA / ACCESS Newswire / May 19, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that it will host a live conference call and webcast at 8:00 a.m. PT/11:00 a.m.

Read More
image for news CASI Pharmaceuticals Provides Business and Clinical Update
CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results
CASI
Published: May 16, 2025 by: Accesswire
Sentiment: Neutral

BEIJING, CN / ACCESS Newswire / May 16, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the quarter ended March 31, 2025. Dr. Wei-Wu He, Ph.D.

Read More
image for news CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results
CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China
CASI
Published: May 12, 2025 by: Accesswire
Sentiment: Neutral

BEIJING, CHINA / ACCESS Newswire / May 12, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it has entered into a definitive Equity and Assets Transfer Agreement (the "Equity and Assets Transfer Agreement") with Kaixin Pharmaceuticals Inc. ("Kaixin Pharmaceuticals"), a Cayman Islands incorporated entity wholly-owned by Dr. Wei-Wu He, Chairman of the board of directors and CEO of the Company and two direct wholly-owned subsidiaries of the Company in China (the "Target Companies"), pursuant to which the Company shall sell …

Read More
image for news CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China

About CASI Pharmaceuticals, Inc. (CASI)

  • IPO Date 1996-06-12
  • Website https://www.casipharmaceuticals.com
  • Industry Biotechnology
  • CEO Wei-Wu He
  • Employees 233
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.